PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS
申请人:ELI LILLY AND COMPANY
公开号:EP1255735A2
公开(公告)日:2002-11-13
US6800651B2
申请人:——
公开号:US6800651B2
公开(公告)日:2004-10-05
[EN] POTENTIATORS OF GLUTAMATE RECEPTORS<br/>[FR] AGENTS DE POTENTIALISATION DE RECEPTEURS DE GLUTAMATE
申请人:LILLY CO ELI
公开号:WO2001056990A2
公开(公告)日:2001-08-09
The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same for the treatment of eg. anxiety, migraine, schizophrenia or epilepsy.
Potentiators of glutamate receptors
申请人:——
公开号:US20040006114A1
公开(公告)日:2004-01-08
The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
1
本发明涉及代谢型谷氨酸受体功能的增强剂,具体提供了化合物I的公式、其组合物以及使用方法。
Synthesis and biological evaluation of nusbiarylin derivatives as bacterial rRNA synthesis inhibitor with potent antimicrobial activity against MRSA and VRSA
作者:Yangyi Qiu、Adrian Jun Chu、Tsz Fung Tsang、Yingbo Zheng、Nga Man Lam、Kendra Sek Lam Li、Margaret Ip、Xiao Yang、Cong Ma
DOI:10.1016/j.bioorg.2022.105863
日期:2022.7
exhibited the best antimicrobialactivity with a minimum inhibitory concentration (MIC) of 0.5 μg/mL. Diverse mechanistic studies validated the capability of 22r inhibiting the function of NusB protein and bacterial rRNA synthesis. In silico study of drug-like properties also provided promising results. Overall, this series of derivatives showed potentialantimicrobialactivity and drug-likeness and